{"id":"elobixibat","rwe":[{"pmid":"41809226","year":"2026","title":"Ileal bile acid transporter inhibitors for chronic constipation in the elderly.","finding":"","journal":"World journal of gastrointestinal pharmacology and therapeutics","studyType":"Clinical Study"},{"pmid":"41594330","year":"2026","title":"Short-Term Efficacy and Safety of Elobixibat for Chronic Constipation Assessed by Rectal Ultrasonography: A Retrospective Observational Study.","finding":"","journal":"Diagnostics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41404536","year":"2025","title":"Update on the Treatment of Autonomic Disorders.","finding":"","journal":"Current treatment options in neurology","studyType":"Clinical Study"},{"pmid":"41261564","year":"2026","title":"Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in Asia.","finding":"","journal":"Journal of neurogastroenterology and motility","studyType":"Clinical Study"},{"pmid":"41165844","year":"2026","title":"Cost-utility analysis of treatment strategies for chronic constipation in Japan.","finding":"","journal":"Journal of gastroenterology","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Ileal sodium/bile acid cotransporter","category":"target"},{"label":"SLC10A2","category":"gene"},{"label":"A06AX09","category":"atc"},{"label":"Active","category":"status"},{"label":"Chronic constipation","category":"indication"},{"label":"EA Pharma","category":"company"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":54.108,"date":"","count":9,"signal":"Pleurothotonus","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=54)"}],"commonSideEffects":[{"effect":"Pleurothotonus","drugRate":"LLR 54","severity":"common"}]},"trials":[],"aliases":[],"company":"EA Pharma","patents":[],"pricing":[],"allNames":"goofice","offLabel":[],"synonyms":["elobixibat","elobixibat hydrate","A3309","AZD7806","AJG533","goofice"],"timeline":[{"date":"2018-01-19","type":"positive","source":"DrugCentral","milestone":"PMDA approval (EA Pharma)"}],"approvals":[{"date":"2018-01-19","orphan":false,"company":"EA Pharma","regulator":"PMDA"}],"brandName":"Goofice","ecosystem":[{"indication":"Chronic constipation","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Ileal sodium/bile acid cotransporter","targets":[{"gene":"SLC10A2","source":"DrugCentral","target":"Ileal sodium/bile acid cotransporter","protein":"Ileal sodium/bile acid cotransporter"}],"modality":"Small Molecule","explanation":"Imagine your intestines as a highway where bile acids are like cars. Normally, these cars get picked up and reabsorbed, but Goofice blocks this process, causing the cars to pile up and stimulate the intestines to move them along, resulting in a bowel movement.","oneSentence":"Goofice works by inhibiting the ileal sodium/bile acid cotransporter to stimulate bowel movements.","technicalDetail":"Goofice inhibits the ileal sodium/bile acid cotransporter (IBAT), a protein responsible for reabsorbing bile acids in the ileum, thereby reducing bile acid reabsorption and increasing bile acid excretion, which stimulates intestinal motility and promotes bowel movements."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5277","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ELOBIXIBAT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELOBIXIBAT","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:58:13.107214","biosimilars":[],"competitors":[{"drugName":"glycerol","drugSlug":"glycerol","fdaApproval":"1982-05-06","patentExpiry":"Sep 22, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lubiprostone","drugSlug":"lubiprostone","fdaApproval":"2006-01-31","patentExpiry":"Oct 25, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"linaclotide","drugSlug":"linaclotide","fdaApproval":"2012-08-30","patentExpiry":"Oct 30, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"prucalopride","drugSlug":"prucalopride","fdaApproval":"2018-12-14","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tegaserod","drugSlug":"tegaserod","fdaApproval":"2002-07-24","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"plecanatide","drugSlug":"plecanatide","fdaApproval":"2017-01-19","patentExpiry":"Sep 15, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tenapanor","drugSlug":"tenapanor","fdaApproval":"2019-09-12","patentExpiry":"Nov 26, 2042","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"elobixibat","indications":{"approved":[{"name":"Chronic constipation","source":"DrugCentral","snomedId":236069009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"glycerol","brandName":"glycerol","genericName":"glycerol","approvalYear":"1982","relationship":"same-class"},{"drugId":"lubiprostone","brandName":"lubiprostone","genericName":"lubiprostone","approvalYear":"2006","relationship":"same-class"},{"drugId":"linaclotide","brandName":"linaclotide","genericName":"linaclotide","approvalYear":"2012","relationship":"same-class"},{"drugId":"prucalopride","brandName":"prucalopride","genericName":"prucalopride","approvalYear":"2018","relationship":"same-class"},{"drugId":"tegaserod","brandName":"tegaserod","genericName":"tegaserod","approvalYear":"2002","relationship":"same-class"},{"drugId":"plecanatide","brandName":"plecanatide","genericName":"plecanatide","approvalYear":"2017","relationship":"same-class"},{"drugId":"tenapanor","brandName":"tenapanor","genericName":"tenapanor","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04006145","phase":"PHASE2","title":"A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH","status":"COMPLETED","sponsor":"Albireo","startDate":"2019-06-06","conditions":["NAFLD","NASH"],"enrollment":47,"completionDate":"2020-07-15"},{"nctId":"NCT06436833","phase":"NA","title":"Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen","status":"RECRUITING","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2024-05-24","conditions":["Bowel Preparation Solution","Colonoscopy"],"enrollment":360,"completionDate":"2024-12-31"},{"nctId":"NCT01069783","phase":"PHASE2","title":"Study of A3309 in Patients With Dyslipidemia","status":"COMPLETED","sponsor":"Albireo","startDate":"2010-02","conditions":["Dyslipidemia"],"enrollment":36,"completionDate":"2010-09"},{"nctId":"NCT05895877","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation","status":"UNKNOWN","sponsor":"Synmosa Biopharma Corp.","startDate":"2021-12-21","conditions":["Constipation"],"enrollment":351,"completionDate":"2023-09-30"},{"nctId":"NCT05703464","phase":"PHASE4","title":"Elobixibat for Chronic Constipation Without Defecation Desire","status":"TERMINATED","sponsor":"International University of Health and Welfare","startDate":"2023-02-09","conditions":["Chronic Constipation"],"enrollment":40,"completionDate":"2023-03-03"},{"nctId":"NCT04784780","phase":"PHASE4","title":"Long-term Elobixibat for Chronic Constipation","status":"UNKNOWN","sponsor":"Yokohama City University","startDate":"2021-08-06","conditions":["Chronic Constipation"],"enrollment":100,"completionDate":"2023-11-30"},{"nctId":"NCT05165199","phase":"PHASE4","title":"Elobixibat for Chronic Constipation Without Defecation Desire","status":"UNKNOWN","sponsor":"Yokohama City University","startDate":"2022-03-01","conditions":["Chronic Constipation"],"enrollment":40,"completionDate":"2023-03"},{"nctId":"NCT04235205","phase":"PHASE2","title":"Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Yokohama City University","startDate":"2020-01-29","conditions":["Nonalcoholic Fatty Liver","Nonalcoholic Steatohepatitis"],"enrollment":102,"completionDate":"2021-09-30"},{"nctId":"NCT01038687","phase":"PHASE2","title":"Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation","status":"COMPLETED","sponsor":"Michael Camilleri, MD","startDate":"2010-01","conditions":["Functional Constipation"],"enrollment":36,"completionDate":"2011-01"},{"nctId":"NCT01007123","phase":"PHASE2","title":"Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation","status":"COMPLETED","sponsor":"Albireo","startDate":"2009-11","conditions":["Constipation","Chronic Constipation"],"enrollment":190,"completionDate":"2010-10"},{"nctId":"NCT01895543","phase":"PHASE3","title":"Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2013-09","conditions":["Chronic Idiopathic Constipation"],"enrollment":411,"completionDate":"2015-05"},{"nctId":"NCT01833065","phase":"PHASE3","title":"Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2013-04","conditions":["Chronic Idiopathic Constipation"],"enrollment":314,"completionDate":"2014-04"},{"nctId":"NCT01827592","phase":"PHASE3","title":"26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2013-04","conditions":["Chronic Idiopathic Constipation"],"enrollment":376,"completionDate":"2014-05"},{"nctId":"NCT02392546","phase":"PHASE2","title":"Elobixibat Colonic Motor Function Study","status":"WITHDRAWN","sponsor":"Ferring Pharmaceuticals","startDate":"2015-04","conditions":["Chronic Idiopathic Constipation"],"enrollment":0,"completionDate":"2016-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"865UEK4EJC","INN_ID":"9414","UMLSCUI":"C3659266","ChEMBL_ID":"CHEMBL3039515","KEGG_DRUG":"D10795","DRUGBANK_ID":"DB12486","PUBCHEM_CID":"9939892","IUPHAR_LIGAND_ID":"9996","MESH_SUPPLEMENTAL_RECORD_UI":"C581303"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"EA Pharma","relationship":"Current Owner"}],"publicationCount":86,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"A06AX09","allCodes":["A06AX09"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 5","pmid":"41809226","title":"Ileal bile acid transporter inhibitors for chronic constipation in the elderly.","journal":"World journal of gastrointestinal pharmacology and therapeutics"},{"date":"2026 Jan 21","pmid":"41594330","title":"Short-Term Efficacy and Safety of Elobixibat for Chronic Constipation Assessed by Rectal Ultrasonography: A Retrospective Observational Study.","journal":"Diagnostics (Basel, Switzerland)"},{"date":"2025","pmid":"41404536","title":"Update on the Treatment of Autonomic Disorders.","journal":"Current treatment options in neurology"},{"date":"2026 Jan 30","pmid":"41261564","title":"Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in Asia.","journal":"Journal of neurogastroenterology and motility"},{"date":"2026 Jan","pmid":"41165844","title":"Cost-utility analysis of treatment strategies for chronic constipation in Japan.","journal":"Journal of gastroenterology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"EA Pharma","companyId":"ea-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Goofice (Elobixibat) is a small molecule modality developed by EA Pharma, targeting the ileal sodium/bile acid cotransporter. It is used to treat chronic constipation. The commercial status of Goofice is patented, with EA Pharma being the current owner. Key safety considerations include the need for further research on its long-term effects. Goofice works by inhibiting the ileal sodium/bile acid cotransporter, which reduces bile acid reabsorption and increases bile acid excretion, thereby stimulating intestinal motility and promoting bowel movements.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2018-01-19T00:00:00.000Z","mah":"EA Pharma","brand_name_local":null,"application_number":""}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}